Skip to content
Study details
Enrolling now

Antiviral Clinical Trial for Long Covid-19

Icahn School of Medicine at Mount Sinai
NCT IDNCT06511063ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

90

Study length

about 1.3 years

Ages

18+

Locations

1 site in NY

About this study

This trial is testing if two repurposed HIV antivirals can reduce symptom burden in adults with Long Covid compared to placebo. Participants will be randomly assigned to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine), Selzentry, or a placebo taken daily for 90 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take Selzentry
  • 3.Take tenofovir disoproxil/emtricitabine
PhasePhase 2
Drugemtricitabine
Routeoral
Primary goalEuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

emtricitabine, tenofovir disoproxil

Drug routes

oral (Oral Capsule)

Endpoints

Primary: EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale

Secondary: Composite Autonomic Symptom Score 31(COMPASS-31), Fatigue Severity Scale (FSS), Fatigue Visual Analogue Scale (F-VAS), General Symptom Questionnaire (GSQ-30), Generalized Anxiety Disorder (GAD-7), Neuro-QoL™ v2.0 Cognitive Function-Short Form, Pain Visual Analogue Scale (P-VAS), Patient Health Questionnaire (PHQ-9)